While peptide- and antigen-focused vaccines like GVAX (GM-CSF-secreting vaccine) [65] or Melan-A/MART-1 and gp100 Peptides [66] are being explored, dendritic cell vaccines have not shown sufficient promise to remain a focus in melanoma immunotherapy. This evidence concerns the gene MLANA and melanoma.